| __timestamp | Corcept Therapeutics Incorporated | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 16758000 |
| Thursday, January 1, 2015 | 36949000 | 17793000 |
| Friday, January 1, 2016 | 45240000 | 18761000 |
| Sunday, January 1, 2017 | 62416000 | 19287000 |
| Monday, January 1, 2018 | 81289000 | 18707000 |
| Tuesday, January 1, 2019 | 100359000 | 20893000 |
| Wednesday, January 1, 2020 | 105326000 | 25678000 |
| Friday, January 1, 2021 | 122356000 | 29665000 |
| Saturday, January 1, 2022 | 152848000 | 43628000 |
| Sunday, January 1, 2023 | 184259000 | 69135000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, Corcept Therapeutics Incorporated and Geron Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Corcept's SG&A expenses surged by over 400%, reflecting a strategic expansion and investment in operational capabilities. In contrast, Geron Corporation's SG&A expenses increased by approximately 310%, indicating a more conservative growth approach.
Corcept's spending peaked in 2023, reaching nearly five times its 2014 levels, while Geron's expenses, though growing, remained more modest. This divergence highlights Corcept's aggressive market positioning compared to Geron's steady, albeit slower, growth. These trends offer insights into each company's strategic priorities and market positioning, providing investors and industry analysts with valuable context for future performance expectations.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for MorphoSys AG and Geron Corporation